These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19884628)

  • 21. [Modern therapy of rheumatoid arthritis. Joint destruction can be delayed].
    Neumaier J
    MMW Fortschr Med; 2008 Apr; 150(14):14. PubMed ID: 18488571
    [No Abstract]   [Full Text] [Related]  

  • 22. Improvement at Any Cost? The Art and Science of Choosing Treatment Strategies for Rheumatoid Arthritis.
    Losina E; Katz JN
    Ann Intern Med; 2017 Jul; 167(1):55-56. PubMed ID: 28554193
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost effectiveness analysis of drug therapies for rheumatoid arthritis.
    Criswell LA; Such CL
    J Rheumatol Suppl; 1996 Mar; 44():52-5. PubMed ID: 8833053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rheumatoid arthritis: strategy more important than agent.
    Sokka T; Pincus T
    Lancet; 2009 Aug; 374(9688):430-2. PubMed ID: 19665630
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
    Merkesdal S; Kirchhoff T; Wolka D; Ladinek G; Kielhorn A; Rubbert-Roth A
    Eur J Health Econ; 2010 Feb; 11(1):95-104. PubMed ID: 19967426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologics in rheumatoid arthritis: where are we going?
    Fechtenbaum M; Nam JL; Emery P
    Br J Hosp Med (Lond); 2014 Aug; 75(8):448-9, 451-6. PubMed ID: 25111096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab cost-effectiveness/safety?
    Rothschild BM
    Rheumatology (Oxford); 2003 Dec; 42(12):1572-3; author reply 1573-4. PubMed ID: 14645868
    [No Abstract]   [Full Text] [Related]  

  • 29. Costs of rheumatoid arthritis in Hungary.
    Péntek M; Kobelt G; Czirják L; Szekanecz Z; Poór G; Rojkovich B; Polgár A; Genti G; Kiss CG; Brodszky V; Májer I; Gulácsi L
    J Rheumatol; 2007 Jun; 34(6):1437. PubMed ID: 17552071
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of rheumatoid arthritis.
    Handa R
    Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
    Welsing PM; Severens JL; Hartman M; van Riel PL; Laan RF
    Arthritis Rheum; 2004 Dec; 51(6):964-73. PubMed ID: 15593319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis.
    Zhang W; Shi Q; Zhao LD; Li Y; Tang FL; Zhang FC; Zhang X
    J Clin Rheumatol; 2010 Dec; 16(8):375-8. PubMed ID: 21085018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rheumatoid arthritis: milestones in classification and treatment].
    Fiehn C
    Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health economics: implications for novel antirheumatic therapies.
    Kavanaugh A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv65-9. PubMed ID: 16239392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al.
    Boers M
    Arthritis Rheum; 2009 Nov; 61(11):1616-7; author reply 1617-8. PubMed ID: 19877096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.